Author Schulz-Heddergott, Ramona
-
2017 | Journal Article |
Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells
Kramer, D.; Stark, N. ; Schulz-Heddergott, R.; Erytch, N.; Edmunds, S.; Rossmann, L. & Bastians, H. et al. (2017)
Cell Death and Differentiation, 24(2) pp. 300-316. DOI: https://doi.org/10.1038/cdd.2016.124
Details DOI PMID PMC WoS
-
2017 | Journal Article |
p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo
Alexandrova, E. M.; Mirza, S. A.; Xu, S.; Schulz-Heddergott, R.; Marchenko, N. D. & Moll, U. M. (2017)
Cell Death and Disease, 8 art. e2661. DOI: https://doi.org/10.1038/cddis.2017.80
Details DOI PMID PMC WoS
-
2018 | Journal Article |
Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target
Schulz-Heddergott, R. & Moll, U. M. (2018)
Cancers, 10(6). DOI: https://doi.org/10.3390/cancers10060188
Details DOI PMID PMC
-
2019 | Journal Article
Transformation Mechanisms of the Nfia-ETO2 Fusion Gene Associated with Pediatric Pure Acute Erythroleukemia
Piqué-Borràs, M.-R.; Bagger, F. O.; Bezerra, M. F.; Louwaige, A.; Juge, S.; Nellas, I. & Ivanek, R. et al. (2019)
Blood, 134(Supplement_1) pp. 532-532. DOI: https://doi.org/10.1182/blood-2019-126416
Details DOI
-
2021 | Journal Article | Research Paper |
Hsp90-stabilized MIF supports tumor progression via macrophage recruitment and angiogenesis in colorectal cancer
Klemke, L.; De Oliveira, T.; Witt, D.; Winkler, N.; Bohnenberger, H.; Bucala, R. & Conradi, L.-C. et al. (2021)
Cell Death & Disease, 12(2). DOI: https://doi.org/10.1038/s41419-021-03426-z
Details DOI
-
2021 | Journal Article | Research Paper |
Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosity
Isermann, T.; Şener, Ö. Ç.; Stender, A.; Klemke, L.; Winkler, N.; Neesse, A. & Li, J. et al. (2021)
Nature Communications, 12(1) art. 4019. DOI: https://doi.org/10.1038/s41467-021-24064-1
Details DOI
-
2023 | Journal Article
CDK4/6 inhibition confers protection of normal gut epithelia against gemcitabine and the active metabolite of irinotecan
Blume, J.; Claus, L.; Isermann, T.; Dickmanns, A.; Conradi, L.-C.; Schulz-Heddergott, R. & Dobbelstein, M. (2023)
Cell Cycle, pp. 1-20. DOI: https://doi.org/10.1080/15384101.2023.2217003
Details DOI
-
2024 | Preprint
Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition
Isermann, T.; Schneider, K. L.; Wegwitz, F.; De Oliveira, T.; Conradi, L.-C.; Volk, V.& Feuerhake, F. et al. (2024). DOI: https://doi.org/10.1101/2024.02.22.581507
Details DOI